Subgroup survival analysis indicated that KRAS mutations are associated with significant increases in mortality but there were no differences between blood samples and tumor tissues for OS and PFS, which suggest that blood sampling is suitable for replacing tissue assay. Here, KRAS is linked to neoplasm.